Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Safety and effectiveness of hyaluronic acid dermal filler in correction of moderate-to-severe nasolabial folds in Chinese subjects.

Dai X, Li L, Peterson W, Baumgartner RR, Huang J, Baer-Zwick A, Hoeller S, Ivezic-Schoenfeld Z, Prinz M.

Clin Cosmet Investig Dermatol. 2019 Jan 14;12:57-62. doi: 10.2147/CCID.S187079. eCollection 2019.

2.

Treatment of facial lipoatrophy, morphological asymmetry, or debilitating scars with the hyaluronic acid dermal filler Princess® FILLER.

Kopera D, Ivezic-Schoenfeld Z, Federspiel IG, Grablowitz D, Gehl B, Prinz M.

Clin Cosmet Investig Dermatol. 2018 Nov 27;11:621-628. doi: 10.2147/CCID.S181964. eCollection 2018.

3.

In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11. doi: 10.1128/AAC.00627-16. Print 2016 Jul.

4.

Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.

Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):282-8. doi: 10.1128/AAC.02033-13. Epub 2014 Oct 27.

5.

Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN.

Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95. doi: 10.1128/AAC.00358-13. Epub 2013 Jul 8.

6.

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

Prince WT, Ivezic-Schoenfeld Z, Lell C, Tack KJ, Novak R, Obermayr F, Talbot GH.

Antimicrob Agents Chemother. 2013 May;57(5):2087-94. doi: 10.1128/AAC.02106-12. Epub 2013 Feb 19.

7.

Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics.

Ross JE, Sader HS, Ivezic-Schoenfeld Z, Paukner S, Jones RN.

J Clin Microbiol. 2012 Oct;50(10):3361-4. doi: 10.1128/JCM.01294-12. Epub 2012 Jul 18.

8.

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN.

J Antimicrob Chemother. 2012 May;67(5):1170-5. doi: 10.1093/jac/dks001. Epub 2012 Jan 27.

PMID:
22287234
9.

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.

Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN.

Antimicrob Agents Chemother. 2012 Mar;56(3):1619-23. doi: 10.1128/AAC.05789-11. Epub 2012 Jan 9.

10.

Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit.

Skugor MM, Stimac V, Palej I, Lugarić D, Paljetak HC, Filić D, Modrić M, Dilović I, Gembarovski D, Mutak S, Eraković Haber V, Holmes DJ, Ivezić-Schoenfeld Z, Alihodzić S.

Bioorg Med Chem. 2010 Sep 1;18(17):6547-58. doi: 10.1016/j.bmc.2010.06.050. Epub 2010 Jun 22.

PMID:
20621489

Supplemental Content

Loading ...
Support Center